14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
OKUR vs LGND: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin).
Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OKUR vs LGND. Trailing 12-month operating profitability (OKUR 0.0% vs LGND 14.4%) and valuation multiples (OKUR N/M vs LGND 24.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $5.7B market capitalization and 14.4% operating margin.
OpEx & R&D Reinvestment71.7% of Rev ($182M)
90D Engineering Disclosures0 Published
Investor FAQ OKUR vs LGND Key Questions & Quantitative Answers
As of Nov 20, 2026, Ligand Pharmaceuticals Inc. (LGND) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). OKUR carries a Unified Composite Score of 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin), whereas LGND carries 46.5/100 (HOLD) at $286.85 (24.0x Forward P/E, 14.4% operating margin). Growth vs. Quality Trade-Off: LGND earns the overall head-to-head edge with a stronger Unified Composite Score (46.5/100 HOLD vs. OKUR 36.0/100 SELL) and 0.93β · 38% Vol risk profile, whereas OKUR leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OKUR is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7); meanwhile LGND trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 38.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LGND leads the Growth & Scale pillar: OKUR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LGND at -31.8% YoY revenue growth and +825.0% YoY earnings growth on $254M TTM revenue (86.1% gross margin, 14.4% operating margin). On trailing 12-month operating scale, OKUR generates N/A in USD-normalized revenue versus $254M for LGND. In operating R&D and SG&A reinvestment, OKUR deploys N/A (0 90-day corporate R&D disclosures) versus 71.7% of Rev ($182M) (0 disclosures) for LGND.
LGND screens cheaper on headline valuation multiples. OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LGND trades at 24.0x Forward P/E, 115.2x Trailing P/E, 1.53x PEG, and 26.9x EV/Revenue (22.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OKUR (-55.2% ROE) versus LGND (5.4% ROE) capital efficiency.
In options market volatility and institutional positioning, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk). By comparison, LGND carries 45.4% implied volatility (9th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.93β · 38% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.